Association of Vitamin D Receptor Gene Polymorphism with Renal Cell Carcinoma in Japanese

• Published in: ENDOCRINE JOURNAL Vol. 49; no. 4; pp. 433 - 438
• Main Authors: TOSHIHIRO IKUYAMA, TAKASHI HAMASAKI, HISATO INATOMI, TAKAHIKO KATOH, TETSURO MURATANI, TETSURO MATSUMOTO
• Format: Journal Article
• Language: Japanese
• Published: The Japan Endocrine Society 2002
• ISSN: 0918-8959

Molecular epidemiologic studies have reported a relationship between lα, 25 dihydroxyvitamin D3 (1, 25(OH)2D3) and the development and progression of malignant tumors. (1, 25(OH)2D3) exerts its biological activity by binding the vitamin D receptor (VDR), while recent studies have demonstrated that VDR gene polymorphisms affect serum levels of (1, 25(OH)2D3). Serum levels of (1, 25(OH)2D3) are reported to be significantly lower in patients with renal cell carcinoma (RCC) compared to non-cancer control patients. The purpose of this study was to investigate the TaqI VDR polymorphism in Japanese RCC patients and non-cancer controls in order to determine if an association exists between VDR genotype and the risk of developing RCC as well as clinical risk factors. A total of 102 RCC patients and 204 controls were genotyped for a previously described TaqI restriction fragment length polymorphism (RFLP) of the VDR gene. Products were digested into T allele or the t allele according to the absence or presence of a TaqI restriction site. Individuals were classified as TT, Tt or tt. The genotype TT was statistically more frequent among RCC patients (80.4%) compared to controls (61.8%) (OR = 2.54; 95% CI, 1.44-4.46; p=0.0006). In addition, the occurrence of the genotype TT was significantly higher in patients with rapid-growth-type group (92.1%) compared to slow-growth-type group (73.4%) (OR=4.22; 95% CI, 1.15-15.53; p=0.0175). These data demonstrate that VDR genotype plays an important role in determining the risk of developing more aggressive RCC in Japanese.